Immunoproteasome Activity in Chronic Lymphocytic Leukemia as a Target of the Immunoproteasome-Selective Inhibitors

Targeting proteasome with proteasome inhibitors (PIs) is an approved treatment strategy in multiple myeloma that has also been explored pre-clinically and clinically in other hematological malignancies. The approved PIs target both the constitutive and the immunoproteasome, the latter being present...

Descripción completa

Detalles Bibliográficos
Autores principales: Besse, Andrej, Kraus, Marianne, Mendez-Lopez, Max, Maurits, Elmer, Overkleeft, Herman S., Driessen, Christoph, Besse, Lenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909520/
https://www.ncbi.nlm.nih.gov/pubmed/35269460
http://dx.doi.org/10.3390/cells11050838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909520/
https://www.ncbi.nlm.nih.gov/pubmed/35269460
http://dx.doi.org/10.3390/cells11050838

Ejemplares similares